Nalls Sherbakoff Group’s AbbVie ABBV Stock Holding History

Nalls Sherbakoff Group’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$68.4K	Sell	272 -60	-18%	-$12.9K	0.05%	158
2026 Q1	$72.2K	Hold	332	–	–	0.05%	160
2025 Q4	$75.9K	Sell	332 -243	-42%	-$55.4K	0.05%	165
2025 Q3	$133K	Hold	575	–	–	0.09%	125
2025 Q2	$107K	Hold	575	–	–	0.08%	137
2025 Q1	$120K	Buy	+575	New	+$112K	0.1%	113
2023 Q4	$105K	Hold	675	–	–	0.09%	113
2023 Q3	$101K	Hold	675	–	–	0.1%	111
2023 Q2	$93.1K	Hold	675	–	–	0.09%	115
2023 Q1	$107K	Buy	+675	New	+$103K	0.11%	111
2018 Q4	$83K	Buy	+895	New	+$78.7K	0.13%	90

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Nalls Sherbakoff Group's ABBV Position: Q2 2026 in Review

Nalls Sherbakoff Group reduced its AbbVie (ABBV) stake by 18% in Q2 2026, selling an estimated $12.9K and leaving 272 shares worth $68.4K. The position accounts for 0.05% of the portfolio, ranked #158.

Nalls Sherbakoff Group first reported a position in ABBV in Q4 2018 and has held it in 11 quarters since. The position peaked at $133K in Q3 2025. 4,221 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Nalls Sherbakoff Group held 272 shares of AbbVie worth $68.4K as of Q2 2026.
Nalls Sherbakoff Group sold 60 AbbVie shares in Q2 2026, an estimated $12.9K.
AbbVie made up 0.05% of Nalls Sherbakoff Group's portfolio in Q2 2026, its #158 holding.
Nalls Sherbakoff Group first reported a position in AbbVie in Q4 2018 and has held it in 11 quarters since.
Nalls Sherbakoff Group's AbbVie position peaked at $133K in Q3 2025.
4,221 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Nalls Sherbakoff Group's 13F filing for Q2 2026, filed 17 Aug 2026.